Reuters: Health
Roche's risdiplam met the primary endpoint in a pivotal clinical trial in infants with type 1 spinal muscular atrophy, the Swiss drugmaker said on Thursday.
Roche's risdiplam meets primary endpoint in trial of SMA drug in infants
Roche's risdiplam meets primary endpoint in trial of SMA drug in infants
Reuters: Health
Roche's risdiplam met the primary endpoint in a pivotal clinical trial in infants with type 1 spinal muscular atrophy, the Swiss drugmaker said on Thursday.
Reuters: Health
Roche's risdiplam met the primary endpoint in a pivotal clinical trial in infants with type 1 spinal muscular atrophy, the Swiss drugmaker said on Thursday.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment